PRESS-RELEASE filed Mar 11, 2026 at 07:30 ET
BrainsWay reported strong Q4 and full-year 2025 results with 27% YoY revenue growth to $52.2 million, net income up 161% to $7.6 million, and raised 2026 guidance projecting $66–68 million in revenue (27–30% growth) and Adjusted EBITDA of $12–14 million (86–100% growth). The company also secured FDA clearances for adolescent depression and an accelerated treatment protocol, expanding its market potential.